JPH04144561A - Nutrient transfusion-containing bag - Google Patents
Nutrient transfusion-containing bagInfo
- Publication number
- JPH04144561A JPH04144561A JP2268673A JP26867390A JPH04144561A JP H04144561 A JPH04144561 A JP H04144561A JP 2268673 A JP2268673 A JP 2268673A JP 26867390 A JP26867390 A JP 26867390A JP H04144561 A JPH04144561 A JP H04144561A
- Authority
- JP
- Japan
- Prior art keywords
- transfusion
- fat
- amino acid
- bag
- infusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000015097 nutrients Nutrition 0.000 title abstract description 4
- 150000001413 amino acids Chemical class 0.000 claims abstract description 58
- 238000001802 infusion Methods 0.000 claims description 35
- 235000016709 nutrition Nutrition 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract description 14
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 7
- 238000002156 mixing Methods 0.000 abstract description 4
- 229920003023 plastic Polymers 0.000 abstract description 2
- 239000004033 plastic Substances 0.000 abstract description 2
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 230000001954 sterilising effect Effects 0.000 abstract 1
- 238000004659 sterilization and disinfection Methods 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 description 38
- 235000001014 amino acid Nutrition 0.000 description 38
- 239000003925 fat Substances 0.000 description 25
- 235000019197 fats Nutrition 0.000 description 25
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 10
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 239000004395 L-leucine Substances 0.000 description 5
- 235000019454 L-leucine Nutrition 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 229960002885 histidine Drugs 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 229960000310 isoleucine Drugs 0.000 description 5
- 229960003136 leucine Drugs 0.000 description 5
- 229960004452 methionine Drugs 0.000 description 5
- 239000003549 soybean oil Substances 0.000 description 5
- 235000012424 soybean oil Nutrition 0.000 description 5
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- 229930182844 L-isoleucine Natural products 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- 229930195722 L-methionine Natural products 0.000 description 4
- 229960003767 alanine Drugs 0.000 description 4
- 229960005261 aspartic acid Drugs 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000003978 infusion fluid Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229960004295 valine Drugs 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 3
- 229930064664 L-arginine Natural products 0.000 description 3
- 235000014852 L-arginine Nutrition 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 235000019864 coconut oil Nutrition 0.000 description 3
- 229960003067 cystine Drugs 0.000 description 3
- 201000010063 epididymitis Diseases 0.000 description 3
- 229960002989 glutamic acid Drugs 0.000 description 3
- 229960002449 glycine Drugs 0.000 description 3
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 229960005190 phenylalanine Drugs 0.000 description 3
- 229960002429 proline Drugs 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 229940083466 soybean lecithin Drugs 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 229960004441 tyrosine Drugs 0.000 description 3
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
- -1 L-Cystine L-Glutamic acid L-Proline Chemical compound 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- RRNJROHIFSLGRA-JEDNCBNOSA-N acetic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.NCCCC[C@H](N)C(O)=O RRNJROHIFSLGRA-JEDNCBNOSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229960003646 lysine Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- LTDYEDCDJFHPFI-DKWTVANSSA-N 2-aminoacetic acid;(2s)-2-aminopropanoic acid Chemical compound NCC(O)=O.C[C@H](N)C(O)=O LTDYEDCDJFHPFI-DKWTVANSSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000020937 fasting conditions Nutrition 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、アミノ酸輸液と脂肪輸液を用時に無菌的に混
合し、経静脈投与するための栄養輸液入りバッグに関す
る。DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to a bag containing a nutritional infusion for intravenously administering an amino acid infusion and a fat infusion that are mixed aseptically before use.
栄養源を経口的に摂取できない患者に対して、経静脈的
に栄養を補給するための輸液は種々開発されている。Various infusion solutions have been developed for intravenously supplying nutrients to patients who are unable to take nutritional sources orally.
しかし、アミノ酸輸液と脂肪輸液を栄養学的に好ましい
比率でそれぞれ収容した二室バッグは、未だ開発されて
いない。However, a two-chamber bag containing amino acid infusions and fat infusions in nutritionally favorable ratios has not yet been developed.
患者に投与されたアミノ酸は、蛋白合成に利用されるほ
か、一部は熱源として消費される。そこでアミノ酸を脂
肪又は糖質とともに投与すると、アミノ酸の蛋白合成に
利用さる割合が増加すると言われている。Amino acids administered to patients are used for protein synthesis, and some are consumed as a heat source. Therefore, it is said that when amino acids are administered together with fat or carbohydrates, the proportion of amino acids utilized for protein synthesis increases.
脂肪は、単位重量当たりの熱量が糖質の約2倍であり、
熱源として優れているが、過剰に投与すると臓器への蓄
積や血中中性脂肪(トリグリセリド)の濃度上昇を招く
などの問題がある。Fat has about twice the calorific value per unit weight as carbohydrates,
Although it is excellent as a heat source, there are problems such as excessive administration leading to accumulation in organs and an increase in the concentration of neutral fats (triglycerides) in the blood.
したがって、本発明の課題は、アミノ酸と脂肪の双方が
生体に効率的に利用される比率で、両輸液を無菌的に混
合し投与するための栄養輸液入りバッグを提供すること
にある。Therefore, an object of the present invention is to provide a bag containing a nutritional infusion solution for aseptically mixing and administering both amino acids and fats in a ratio that allows the living body to efficiently utilize both of the infusions.
本発明者らは、上記課題を解決するため、ラットにアミ
ノ酸と脂肪を経静脈的に投与し、窒素出納、DNA対R
NA比、血漿トリグリセリド濃度、臓器中トリグリセリ
ド含量等を指標にして鋭意研究した結果、アミノ酸の投
与量が脂肪の投与量以上のとき好結果が得られるこ々を
見出し、本発明を完成することができた、
すなわち本発明は、アミノ酸輸液申の総アミノ酸重景に
対する脂肪輸液中の総脂肪重【の比率が0.5〜1にな
るように、アミノ酸輸液と脂肪輸液が二室バッグの各室
にそれぞれ収容された栄養輸液入りバッグに関するもの
である。In order to solve the above problems, the present inventors intravenously administered amino acids and fat to rats, and investigated nitrogen balance, DNA vs.
As a result of intensive research using NA ratio, plasma triglyceride concentration, triglyceride content in organs, etc. as indicators, we discovered that good results can be obtained when the dose of amino acids is greater than the dose of fat, and we have completed the present invention. In other words, the present invention is such that the amino acid infusion and the fat infusion are placed in each chamber of the two-chamber bag so that the ratio of the total fat weight in the fat infusion to the total amino acid weight in the amino acid infusion is 0.5 to 1. The invention relates to bags containing nutritional infusions, each housed in a bag containing a nutritional infusion solution.
本発明で使用されるアミノ酸輸液は、必須アミノ酸と非
必須アミノ酸がバランスよく配合され、種々の疾病、売
春に広範に適用されるもの、あるいは術後患者用、肝臓
病患者用、腎臓病患4を川筋特定の疾病患者用として開
発されたものなどいずれでもよい。中でも栄養効果に重
点を置いゾ、−ものが好ましく、例えば下記アミ、ノ酸
組成のものを示すことができる。The amino acid infusion used in the present invention contains a well-balanced combination of essential amino acids and non-essential amino acids, and is widely applicable to various diseases and prostitution, as well as for postoperative patients, liver disease patients, kidney disease patients, etc. Any drug developed for patients with a specific disease may be used. Among them, those with emphasis on nutritional effects are preferred, and for example, those with the following amino acid and no acid compositions can be shown.
アミノ酸
L−イソロイシン
し−ロイシン
L、−リジン
組成
(g/全アミノ酸重罰10h)
4.0〜13.0
10.0−20.0
3.5〜・13.0
I7−メチオニン 1.5〜・10.0■、−
フ又ニルアラニン 3.0〜10.0L−) 1/オ
ニン 3゜0−・・11.0L−hリブ[ファ
ン 0.5−5.0I7−バリン 38
0−16.0L−アルギニン 5.0 = 2
1.0L−−ヒスチジン 2.0〜8.5アミ
ノ酢酸 2,0〜12゜OL−アラニン
3.0〜1560L−−アスパラギン酸
0−・ 4.0L−システィン 0 − 1
.0L−シスチン O−0,3
L−−グルタミン酸 〇 −・ 7゜OL−プロ
リン 165〜・6.01、−−−uリン
0.5〜3.0L−−チロシン
0.1−・5.0アミノ酸輸液の濃度ば、i常5へ
・15(ti/v)%が好ましい。Composition of amino acids L-isoleucine, L-leucine L, and lysine (g/10 hours of severe punishment for all amino acids) 4.0-13.0 10.0-20.0 3.5-・13.0 I7-methionine 1.5-・10.0■, -
Futa Nylalanine 3.0-10.0L-) 1/Onine 3゜0-...11.0L-h Rib [Fan 0.5-5.0I7-valine 38
0-16.0L-arginine 5.0 = 2
1.0L--histidine 2.0-8.5 aminoacetic acid 2.0-12゜OL-alanine
3.0-1560L--aspartic acid
0-・4.0L-cystine 0-1
.. 0L-cystine O-0,3 L--glutamic acid 〇-・7゜OL-proline 165-・6.01, ---u phosphorus
0.5-3.0L--Tyrosine
The concentration of 0.1-5.0 amino acid infusion is preferably 5 to 15 (ti/v)%.
また、脂肪輸液は、例えば大豆油、ヤシ油、ゴマ油、エ
ゴマ油、アマニ油、綿実油、サフラワー油、魚油等を常
法に従っC水中浦型に乳化したものが使用でき、通常5
=20h/υ)%濃度のものが好ま17い。In addition, for fat infusion, for example, soybean oil, coconut oil, sesame oil, perilla oil, linseed oil, cottonseed oil, safflower oil, fish oil, etc. can be emulsified in a C-in-water type according to a conventional method, and usually 5
=20h/υ)% concentration is preferred17.
本発明の栄養輸液入りバッグの製aに当たり、特に困難
はなく、例えば、平均的な成人−・l」当たりのアミノ
酸必要鼠40〜・・80gを含有するアミノ酸輸液忙を
、二室バッグの一室に充填し、そのアミノ酸質の0.5
−・1倍重計の脂肪を含有する脂肪軸液量を、残りの室
に充填して滅菌処理をすればよい。There is no particular difficulty in manufacturing the bag containing the nutritional infusion of the present invention. Fill the chamber with 0.5 of its amino acid
- The remaining chamber may be filled with an amount of fat liquid containing 1 times the weight of fat and sterilized.
二室バッグは、プラスチック製の柔軟な袋状容器であっ
て、その中央部が帯状に剥離可能6二熱溶着され、液密
に隅離されたT′ニー室のそれぞイ1東輸液注入口又は
排出口が設けられたものを使用した。The two-chamber bag is a flexible bag-like container made of plastic, and the central part is heat-welded to two T' knee chambers that can be peeled off in the form of a strip, and each of the two T' knee chambers is separated in a liquid-tight manner. A device with an inlet or outlet was used.
この二室バッグの各室に、下記°アミノ酸輸液と脂肪輸
液を、それぞれ窒素気流中で充填j−密封袋、高圧蒸気
減菌した。Each chamber of this two-chamber bag was filled with the following amino acid infusion and fat infusion in a nitrogen stream, sealed in a sealed bag, and sterilized with high-pressure steam.
実施例1
(1)アミノ酸輸液500扉(充填)中の成分(シ)L
−イソロイシン 4.55
L−ロイシン 6645
酢酸L−リジン 5.00
L−メチオニン 2.20
L〜フy、ニルアラニン 3,50
1、−1−レオニン 3,751、−トリプト
ファン
L−−バリン 7.0O
L−アルギニン へ、50
■5−ヒスチジン 2.50
アミノ酢酸 3、50
■、〜アラニン 3655
1、−アスパラギン酸 0.50
1、− システィン 0.181、・−グルタ
ミン酸 0.25夏、−プロリン
2。50I、−セリン 0685
L−チロシン 0.20
(遊離アミノ酸総重戴 50。18g)11肪輸液
500d (充填)中の成分(g)大豆油
50.0
精製大豆レシチン 6.0
濃グリセリン 12.5
実施例2
(1)アミノ酸輸液5001d (充填)中の成分(g
)L−イソロイシン 2.80
L−ロイシン 6.25
酢酸L−リジン 6.20
L−メチオニン 1.75
L−フェニルアラニン 4.675
L−)レオニン 3.25
L−)リブトファン 0.65
L−バリン 2.25
L−アルギニン 3395
L−ヒスチジン 3.00
アミン酢酸 5.35
L−アラニン 3.10
L−アスパラギン酸 1.90
0.50
3.25
L−システィン
L−グルタミン酸
L−プロリン 1.65
L−セリン 1.1O
L−チロシン 0.175
(遊離アミノ酸総重量 50.00g)(2)脂肪輸
液250m (充填)中の成分(g)エゴマ油
so、o。Example 1 (1) Ingredients (C) L in amino acid infusion 500 doors (filled)
-Isoleucine 4.55 L-Leucine 6645 L-Lysine Acetate 5.00 L-Methionine 2.20 L-phy, Nylalanine 3,50 1,-1-Leonine 3,751, -Tryptophan L--Valine 7.0O L-Arginine, 50 ■5-Histidine 2.50 Aminoacetic acid 3,50 ■, ~Alanine 3655 1,-Aspartic acid 0.50 1,-Cystine 0.181, -Glutamic acid 0.25Summer, -Proline
2.50I, -Serine 0685 L-Tyrosine 0.20 (Total weight of free amino acids 50.18g) 11 Ingredients in fat infusion 500d (filling) (g) Soybean oil
50.0 Purified soybean lecithin 6.0 Concentrated glycerin 12.5 Example 2 (1) Components (g) of amino acid infusion 5001d (filling)
) L-isoleucine 2.80 L-leucine 6.25 L-lysine acetate 6.20 L-methionine 1.75 L-phenylalanine 4.675 L-) leonine 3.25 L-) ribtophan 0.65 L-valine 2 .25 L-Arginine 3395 L-Histidine 3.00 Amineacetic acid 5.35 L-Alanine 3.10 L-Aspartic acid 1.90 0.50 3.25 L-Cystine L-Glutamic acid L-Proline 1.65 L- Serine 1.1O L-Tyrosine 0.175 (Total weight of free amino acids 50.00g) (2) Ingredients in 250m of fat infusion (filled) (g) Perilla oil
So, o.
卵黄レシチン 6.00
濃グリセリン 12.50
実施例3
(1)アミノ酸輸液500m (充填)中の成分(g)
L−イソロイシン 4.60
L−ロイシン 4.725
塩酸L−リジン 1.975
L−メチオニン 0.22
L−フェニルアラニン 0.15
L−)レオニン 1.07
L−)リブトファン 0.35
L−バリン 4.45
し−アルギニン 7 、685L−ヒスチジン
1.55
アミノ酢酸
L−アラニン
2.70
4.20
0.10
2.65
1.30
0.20
37.53g)
中の成分(g)
25.00
3.00
6.25
L−アスパラギン酸
L−プロリン
L−セリン
L−チロシン
(遊離アミノ酸総重量
(2) Flil[[250m (充填)ヤシ油
精製大豆レシチン
濃グリセリン
実施例4
(1)アミノ酸輸液500d (充填)中の成分(g)
L−イソロイシン 3.75
L−ロイシン 5.00
L−リジン 2.50
L−メチオニン 2.50
L−フェニルアラニン 2.50
L−ルオニン 1.25
L−)リプトファン 1.25
L−バリン 3.75
L−アルギニン 1.50
L−ヒスチジン 1.25
アミノ酢酸 0.75
L−アラニン 1.50
L−アスパラギン酸 0.125
L−グルタミン酸 0.125
L−プロリン 1.00
L−セリン 0.50
L−チロシン 0.25
(遊離アミノ酸総重量 29.50g)(2)脂肪輸
液250m (充填)中の成分(g)ヤシ油
25.00
卵黄レシチン 3.00
濃グリセリン 6.25
(試験例)
被験液は、アミノ酸のみ配合した輸液、大豆油のみを水
中油型に乳化した輸液及びアミノ酸と大豆油を比率を変
えて配合した輸液を調製して用いた。Egg yolk lecithin 6.00 Concentrated glycerin 12.50 Example 3 (1) Components (g) in amino acid infusion 500m (filled)
L-isoleucine 4.60 L-leucine 4.725 L-lysine hydrochloride 1.975 L-methionine 0.22 L-phenylalanine 0.15 L-) leonine 1.07 L-) ribtophan 0.35 L-valine 4. 45 Shi-arginine 7, 685 L-histidine 1.55 L-alanine aminoacetate 2.70 4.20 0.10 2.65 1.30 0.20 37.53g) Ingredients (g) 25.00 3. 00 6.25 L-aspartic acid L-proline L-serine L-tyrosine (total weight of free amino acids (2) Flil [250 m (filling) Coconut oil refined soybean lecithin concentrated glycerin Example 4 (1) Amino acid infusion 500 d (filling) ) Ingredients (g)
L-isoleucine 3.75 L-leucine 5.00 L-lysine 2.50 L-methionine 2.50 L-phenylalanine 2.50 L-luonine 1.25 L-)liptophan 1.25 L-valine 3.75 L-Arginine 1.50 L-Histidine 1.25 Aminoacetic acid 0.75 L-Alanine 1.50 L-Aspartic acid 0.125 L-Glutamic acid 0.125 L-Proline 1.00 L-Serine 0.50 L- Tyrosine 0.25 (Total weight of free amino acids 29.50 g) (2) Components in 250 m (filling) of fat infusion (g) Coconut oil
25.00 Egg yolk lecithin 3.00 Concentrated glycerin 6.25 (Test example) The test solutions were an infusion containing only amino acids, an infusion containing only soybean oil as an oil-in-water emulsion, and an infusion containing amino acids and soybean oil in varying ratios. An infusion solution was prepared and used.
但し、アミノ酸の種類と各アミノ酸の配合比率、並びに
大豆油、精製大豆レシチン及び濃グリセリンの配合比率
は、実施例1と同じにした。However, the types of amino acids, the blending ratios of each amino acid, and the blending ratios of soybean oil, purified soybean lecithin, and concentrated glycerin were the same as in Example 1.
試験例1
7週令のSD系m性ラット(1群7匹)を用い、麻酔下
にて中心静態カテ・−チルgと術を施行した。Test Example 1 Using 7-week-old SD rats (7 rats per group), central static catheterization was performed under anesthesia.
引続き絶食下、生理食塩水をlif/hrで1日間投与
した後、被験液を245に6./hrで1日間投与1゜
た。投与終了後、尿、血液及び各臓器を採取し、窒素出
納、肝臓及び筋肉中の[?NA/I)NA比、血漿]・
リグリセリド濃度、肝臓及び胛股;中のトリグリセリド
含髪を測定し、次の結果を得た。Subsequently, physiological saline was administered at lif/hr for 1 day under fasting conditions, and then the test solution was added to 245 ml of 6. The dose was 1°/hr for 1 day. After administration, urine, blood and various organs were collected, and nitrogen balance, liver and muscle [?] were collected. NA/I) NA ratio, plasma]・
Liglyceride concentration and triglyceride content in the liver and thighs were measured, and the following results were obtained.
(1)窒素出納
下記表に示す通り、アミノ酸配合値が脂■jj配合量と
等置以2J二で、正の窒素出納を示j、た。(1) Nitrogen balance As shown in the table below, positive nitrogen balance was shown when the amino acid content was equal to the fat content.
(2)肝臓及び筋肉中のIINA/DNA比アミノ酸配
合量が脂肪配合量と等最以上で、肝臓及び筋肉中のRN
A/Dh比が高い値どなり、蛋白合成の高進が認められ
た。(2) IINA/DNA ratio in the liver and muscle The amino acid content is equal to or higher than the fat content, and the RN in the liver and muscle
A high A/Dh ratio was observed, and protein synthesis was observed to be accelerated.
(3)血弊トリグリセリド濃度
アミノ酸配合量が脂肪配合量と等量以上で、血管トリグ
リセリド濃度は明らかに低トし、血中トリグリセリドの
クリアランスが高進しているこ々が認められた。(3) Blood-related triglyceride concentration When the amino acid content was equal to or greater than the fat content, the vascular triglyceride concentration was clearly lowered, and it was observed that the clearance of blood triglycerides was enhanced.
(4)臓器中のトリグリセリド含量
アミノ酸配合量が脂肪配合量と等猷以上e、肝臓及び肺
臓中のトリグリセリド含量は低い値となり、組織への脂
肪V稍の減少が認められた。(4) Triglyceride content in organs When the amino acid content was equal to or more than the fat content, the triglyceride content in the liver and lungs became a low value, and a decrease in fat V in the tissues was observed.
試験例2
8週令のSD系雄性ラット(1群5匹)を用い、試験例
1と同様にして被験液を投与した。投与終了後、臓器を
採取して、精巣上体脂肪重量、肝臓及び牌に中のトリグ
リセリド含量を測定し、次の結果を得た。Test Example 2 The test solution was administered in the same manner as in Test Example 1 using 8-week-old SD male rats (5 rats per group). After the administration, the organs were collected and the weight of epididymal fat, the triglyceride content in the liver and the tile were measured, and the following results were obtained.
(1)精巣上体脂肪重量
脂肪配合量がアミノ酸配合量を超えると、精巣上体脂肪
重量が顕著に増加し、脂肪組織^、のl1i1肋蓄積が
推測された。(1) Epididymal fat weight When the fat content exceeds the amino acid content, the epididymal fat weight increases markedly, and it is assumed that L1i1 rib accumulation of adipose tissue occurs.
(2)臓器中のトリグリセリド含量
脂肪配合量がアミノ酸配合量を超えると、肝臓及び肺臓
中のトリグリセリド含量が顕著に増加し、組織への脂肪
蓄積が認められた。(2) Triglyceride content in organs When the fat content exceeded the amino acid content, the triglyceride content in the liver and lungs increased significantly, and fat accumulation in the tissues was observed.
以上の結果から、栄養輸液におけるアミノ酸投与量に対
する脂肪の投与量は、0.5〜1倍が好ましいことが推
定された。From the above results, it was estimated that the amount of fat administered in the nutritional infusion is preferably 0.5 to 1 times the amount of amino acid administered.
本発明によれば、二室バッグの隔離手段を開通させるこ
とによってアミノ酸輸液と脂肪輸液を無菌的に混合でき
、生体にとって好ましい比率で窒素源と熱源を安全に投
与することができる。According to the present invention, the amino acid infusion and the fat infusion can be mixed aseptically by opening the isolation means of the two-chamber bag, and the nitrogen source and heat source can be safely administered at a ratio favorable to the living body.
特許出願人 森下製薬株式会社Patent applicant: Morishita Pharmaceutical Co., Ltd.
Claims (1)
液中の総脂肪重量の比率が0.5〜1になるように、ア
ミノ酸輸液と脂肪輸液が二室バッグの各室にそれぞれ収
容された栄養輸液入りバッグ。(1) A nutritional infusion in which an amino acid infusion and a fat infusion are stored in each chamber of a two-chamber bag so that the ratio of the total fat weight in the fat infusion to the total amino acid weight in the amino acid infusion is 0.5 to 1. bag.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2268673A JP3049280B2 (en) | 1990-10-05 | 1990-10-05 | Nutrition infusion bag |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2268673A JP3049280B2 (en) | 1990-10-05 | 1990-10-05 | Nutrition infusion bag |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH04144561A true JPH04144561A (en) | 1992-05-19 |
JP3049280B2 JP3049280B2 (en) | 2000-06-05 |
Family
ID=17461807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2268673A Expired - Lifetime JP3049280B2 (en) | 1990-10-05 | 1990-10-05 | Nutrition infusion bag |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3049280B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995028906A1 (en) * | 1994-04-20 | 1995-11-02 | The Green Cross Corporation | Transfusion container, transfusion preparation, and comprehensive vitamin-containing high-calorie transfusion preparation |
-
1990
- 1990-10-05 JP JP2268673A patent/JP3049280B2/en not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995028906A1 (en) * | 1994-04-20 | 1995-11-02 | The Green Cross Corporation | Transfusion container, transfusion preparation, and comprehensive vitamin-containing high-calorie transfusion preparation |
US5728681A (en) * | 1994-04-20 | 1998-03-17 | The Green Cross Corporation | Infusion preparation and two compartment container containing the preparation |
Also Published As
Publication number | Publication date |
---|---|
JP3049280B2 (en) | 2000-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0347890B1 (en) | Amino acid nutrient compositions | |
MX2008013540A (en) | Paediatric amino acid solution for parenteral nutrition. | |
WO1994008548A1 (en) | Transfusion liquid-containing holder and prepared transfusion liquid | |
CN101015501B (en) | Injection composition of fat milk, amino acid and glucose packed with three-cavity bag and preparing method thereof | |
CN100467012C (en) | Separately packed structural fatty milk, aminoacid and glucose injection composition and the prepn process | |
ES2974910T3 (en) | Parenteral nutrition formulation with optimized amino acid and glucose content | |
CN101019822A (en) | Separately packed fatty milk, amino acid and glucose injection composition and the prepn process | |
JPH06312923A (en) | Nutritional infusion for peripheral intravenous administration | |
JP3937423B2 (en) | Amino acid-containing albumin preparation | |
JPH04144561A (en) | Nutrient transfusion-containing bag | |
JPH03204814A (en) | Oral amino acid preparation for cardiac failure | |
JPS61501558A (en) | Parenteral nutritional supplementation of medium and long chain triglycerides | |
JPH08175987A (en) | Oral and enteral nutritive composition | |
JP2683129B2 (en) | Nutrition composition | |
JP3914585B2 (en) | Macrophage nitric oxide production enhancer | |
JPH07330583A (en) | Liquid preparation containing free glutamic acid | |
JPS61502822A (en) | Total parenteral and enteral nutrition compositions | |
JP2007262088A (en) | Nutrition transfusion formulation | |
JP2001079064A (en) | Infusion solution container | |
JP2000143509A (en) | Nutrient infusion preparation | |
KR20110131697A (en) | Method for preparing intravenous infusion containing bile acid, derivatives thereof or salts thereof | |
JP4148632B2 (en) | Peripheral parenteral nutrition infusion | |
CN101332195B (en) | Compound branched chain amino acid injection | |
JP4187957B2 (en) | Choline combination infusion | |
JP2744662B2 (en) | Nutrition composition |